DaVita (NYSE:DVA – Get Free Report) is scheduled to be announcing its earnings results after the market closes on Tuesday, October 29th. Analysts expect the company to announce earnings of $2.76 per share for the quarter. DaVita has set its FY24 guidance at $9.25-10.05 EPS and its FY 2024 guidance at 9.250-10.050 EPS.Investors interested in participating in the company’s conference call can do so using this link.
DaVita (NYSE:DVA – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.47 by $0.12. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The company had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.15 billion. During the same period in the previous year, the business earned $2.08 EPS. DaVita’s revenue for the quarter was up 6.2% compared to the same quarter last year. On average, analysts expect DaVita to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.
DaVita Price Performance
DVA stock opened at $156.99 on Monday. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. DaVita has a 52-week low of $75.47 and a 52-week high of $168.50. The stock’s 50 day moving average is $158.09 and its two-hundred day moving average is $145.67. The company has a market capitalization of $13.77 billion, a PE ratio of 17.84, a P/E/G ratio of 0.93 and a beta of 0.87.
Insider Transactions at DaVita
Wall Street Analysts Forecast Growth
DVA has been the topic of several analyst reports. UBS Group lifted their price objective on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Bank of America boosted their price objective on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. Truist Financial boosted their price objective on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Finally, TD Cowen boosted their price target on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, DaVita presently has a consensus rating of “Hold” and a consensus target price of $159.00.
Read Our Latest Research Report on DVA
About DaVita
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Read More
- Five stocks we like better than DaVita
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Upcoming IPO Stock Lockup Period, Explained
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How to Capture the Benefits of Dividend Increases
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.